



Monobind Inc.
Lake Forest, CA 92630, USA

AccuLite
CLIA Microwells

Carcinoembryonic Antigen (CEA)
Test System
Product Code: 1875-300

1.0 INTRODUCTION

Intended Use: The Quantitative Determination of Carcinoembryonic Antigen (CEA) Concentration in Human Serum by a Microplate Enzyme Immunoassay, Chemiluminescence.

2.0 SUMMARY AND EXPLANATION OF THE TEST

Carcinoembryonic antigen (CEA) is comprised of a heterogeneous family of glycoproteins with a molecular weight ranging from 175 to 200 kD due to variations in its carbohydrate and amino acid content. CEA is the first of the so-called carcinoembryonic proteins that was discovered in 1965 by Gold and Freeman.¹ Even though its biological function is not very well defined CEA is the most widely used marker for colo-rectal cancer.

Although CEA is primarily associated with colorectal cancers (CRC), other malignancies that can cause elevated levels of CEA include breast, lung, stomach, pancreas, ovary and other organs. Benign conditions that cause significantly higher than normal levels include inflammation of lung and gastrointestinal (GI) tract and benign liver cancer.^{2,3} Heavy Smokers, as a group, have higher than normal baseline concentration of CEA. Serum values in healthy adults are normally ≤ 5.0 ng/ml however, serum values exceeding 5 times the normal reference range are taken as indicative of malignancy. Also, values seen in malignant and non-malignant conditions can overlap thus making CEA a not very dependable marker for malignancy. However, the real importance of CEA testing lies in patient prognosis, status assessment and monitoring. Monitoring CEA levels during chemotherapy and before surgery can be informative; the failure of CEA levels to fall during pre-operative radiotherapy usually indicates the presence of a tumor outside the field of radiation and a poor prognosis. Levels have been seen to drop to normal in 4-6 weeks after a successful resection of CRC.

In this method, CEA calibrator, patient specimen or control is first added to a streptavidin coated well. Biotinylated monoclonal and enzyme labeled antibodies (directed against distinct and different epitopes of CEA) are added and the reactants mixed. Reaction between the various CEA antibodies and native CEA forms a sandwich complex that binds with the streptavidin coated to the well.

After the completion of the required incubation period, the enzyme-CEA antibody bound conjugate is separated from the unbound enzyme-CEA conjugate by aspiration or decantation. The activity of the enzyme present on the surface of the well is quantitated by reaction with a suitable substrate to produce light.


The employment of several serum references of known carcinoembryonic antigen (CEA) levels permits the construction of a dose response curve of activity and concentration. From comparison to the dose response curve, an unknown specimen's activity can be correlated with CEA concentration.

3.0 PRINCIPLE

Immunoenzymometric assay (Type 3):

The essential reagents required for an immunoenzymometric luminescence assay include high affinity and specificity antibodies (enzyme and immobilized), with different and distinct epitope recognition, **in excess**, and native antigen. In this procedure, the immobilization takes place during the assay at the surface of a microplate well through the interaction of streptavidin coated on the well and exogenously added biotinylated monoclonal anti-CEA antibody.

Upon mixing monoclonal biotinylated antibody, the enzyme-labeled antibody and a serum containing the native antigen, reaction results between the native antigen and the antibodies, without competition or steric hindrance, to form a soluble sandwich complex. The interaction is illustrated by the following equation:



$\text{BiotAb}_{(m)}$ = Biotinylated Monoclonal Antibody (Excess Quantity)

Ag_{CEA} = Native Antigen (Variable Quantity)

EnzAb = Enzyme labeled Antibody (Excess Quantity)

$\text{EnzAb} - \text{Ag}_{\text{CEA}} - \text{BiotAb}_{(m)}$ = Antigen-Antibodies Sandwich Complex

k_a = Rate Constant of Association

k_{-a} = Rate Constant of Dissociation

Simultaneously, the complex is deposited to the well through the high affinity reaction of streptavidin and biotinylated antibody. This interaction is illustrated below:

$\text{EnzAb} - \text{Ag}_{\text{CEA}} - \text{BiotAb}_{(m)} + \text{Streptavidin}_{\text{CW}} \rightleftharpoons \text{Immobilized complex}$
 $\text{Streptavidin}_{\text{CW}}$ = Streptavidin immobilized on well
 Immobilized complex = sandwich complex bound to the well

After equilibrium is attained, the antibody-bound fraction is separated from unbound antigen by decantation or aspiration. The enzyme activity, in the antibody-bound fraction, is directly proportional to the native antigen concentration. The enzyme activity is determined by reaction with a light emitting substrate. By utilizing several different serum references of known antigen values, a dose response curve can be generated from which the antigen concentration of an unknown can be ascertained.

4.0 REAGENTS

Materials Provided:

A. CEA Calibrators – 1 ml/vial Icons A-F

Six (6) vials of references CEA Antigen at levels of 0 (A), 5 (B), 10 (C), 25 (D), 50 (E) and 250 (F) ng/ml. Store at 2-8 °C. A preservative has been added.

Note: The calibrators, human serum based, were calibrated using a reference preparation, which was assayed against the 1st International Reference Preparation (IRP# 73/601).

B. CEA Tracer Reagent – 13 ml/vial – Icon

One (1) vial containing enzyme labeled antibody, biotinylated monoclonal mouse IgG in buffer, dye, and preservative. Store at 2-8 °C.

C. Light Reaction Wells – 96 wells – Icon

One 96-well white microplate coated with streptavidin and packaged in an aluminum bag with a drying agent. Store at 2-8 °C.

D. Wash Solution Concentrate – 20 ml/vial – Icon

One (1) vial containing a surfactant in buffered saline. A preservative has been added. Store at 2-8 °C. (See Reagent Preparation Section)

E. Signal Reagent A – 7ml/vial – Icon

One (1) vial containing luminol in buffer. Store at 2-8 °C. (See Reagent Preparation Section)

F. Signal Reagent B – 7ml/vial – Icon

One (1) vial containing hydrogen peroxide (H₂O₂) in buffer. Store at 2-8 °C. (See Reagent Preparation Section)

G. Product Inert

Note 1: Do not use reagents beyond the kit expiration date.

Note 2: Avoid extended exposure to heat and light. **Opened reagents are stable for sixty (60) days when stored at 2-8°C. Kit and component stability are identified on the label.**

Note 3: Above reagents are for a single 96-well microplate

4.1 Required but NOT provided:

1. Pipette capable of delivering 0.025 ml (25 μ l) volumes with a precision of better than 1.5%.
2. Dispenser(s) for repetitive deliveries of 0.100ml and 0.350ml volumes with a precision of better than 1.5%.
3. Microplate washer or a squeeze bottle (optional).
4. Microplate luminometer
5. Absorbent Paper for blotting the microplate wells.
6. Plastic wrap or microplate cover for incubation steps.
7. Vacuum aspirator (optional) for wash steps.
8. Timer.
9. Quality control materials.

5.0 PRECAUTIONS

**For In Vitro Diagnostic Use
Not for Internal or External Use in Humans or Animals**

All products that contain human serum have been found to be non-reactive for Hepatitis B Surface Antigen, HIV 1&2 and HCV Antibodies by FDA licensed reagents. Since no known test can offer complete assurance that infectious agents are absent, all human serum products should be handled as potentially hazardous and capable of transmitting disease. Good laboratory procedures for handling blood products can be found in the Center for Disease Control / National Institute of Health, "Biosafety in Microbiological and Biomedical Laboratories," 2nd Edition, 1988, HHS Publication No. (CDC) 88-8395.

Safe disposal of kit components must be according to local regulatory and statutory requirement.

6.0 SPECIMEN COLLECTION AND PREPARATION

The specimens shall be blood, serum in type and the usual precautions in the collection of venipuncture samples should be observed. For accurate comparison to established normal values, a fasting morning serum sample should be obtained. The blood should be collected in a plain redtop venipuncture tube without additives or anti-coagulants. Allow the blood to clot. Centrifuge the specimen to separate the serum from the cells.

In patients receiving therapy with high biotin doses (i.e. >5mg/day), no sample should be taken until at least 8 hours after the last biotin administration, preferably overnight to ensure fasting sample.

Samples may be refrigerated at 2-8 °C for a maximum period of five (5) days. If the specimen(s) cannot be assayed within this time, the sample(s) may be stored at temperatures of -20°C for up to 30 days. Avoid use of contaminated devices. Avoid repetitive freezing and thawing. When assayed in duplicate, 0.050 ml (50 μ l) of the specimen is required.

7.0 QUALITY CONTROL

Each laboratory should assay controls at levels in the low, medium and high ranges of the dose response curve for monitoring assay performance. These controls should be treated as unknowns and values determined in every test procedure performed. Quality control charts should be maintained to follow the performance of the supplied reagents. Pertinent statistical methods should be employed to ascertain trends. Significant deviation from established performance can indicate unnoticed change in experimental conditions or degradation of kit reagents. Fresh reagents should be used to determine the reason for the variations.

8.0 REAGENT PREPARATION

1. **Wash Buffer**
Dilute contents of Wash Concentrate to 1000ml with distilled or deionized water in a suitable storage container. Store at 2-8 °C for up to 60 days.
2. **Working Signal Reagent Solution** - Store at 2-8 °C.
Determine the amount of reagent needed and prepare by mixing equal portions of Signal Reagent A and Signal Reagent B in a clean container. For example, add 1 ml of A and 1ml of B per two (2) eight well strips. (A slight excess of solution is made.) **Discard the unused portion if not used within 36 hours after mixing. If complete utilization of the reagents is anticipated, within the above time constraint, pour the contents**

of Signal Reagent B into Signal Reagent A and label accordingly.

Note: do not use reagents that are contaminated or have bacteria growth.

9.0 TEST PROCEDURE

*Before proceeding with the assay, bring all reagents, serum reference calibrators and controls to room temperature (20-27°C). ****Test Procedure should be performed by a skilled individual or a trained professional*****

1. Format the microplates' wells for each serum reference calibrator, control and patient specimen to be assayed in duplicate. **Replace any unused microwell strips back into the aluminum bag, seal and store at 2-8°C.**
2. Pipette 0.025 ml (25 μ l) of the appropriate serum reference calibrator, control or specimen into the assigned well.
3. Add 0.100 ml (100 μ l) of the CEA Tracer Reagent to each well. **It is very important to dispense all reagents close to the bottom of the coated well.**
4. Swirl the microplate gently for 20-30 seconds to mix and cover.
5. Incubate 45 minutes at room temperature.
6. Discard the contents of the microplate by decantation or aspiration. If decanting, tap and blot the plate dry with absorbent paper.
7. Add 0.350ml (350 μ l) of wash buffer (see Reagent Preparation Section), decant (tap and blot) or aspirate. Repeat four (4) additional times for a total of five (5) washes. **An automatic or manual plate washer can be used. Follow the manufacturer's instruction for proper usage. If a squeeze bottle is employed, fill each well by depressing the container (avoiding air bubbles) to dispense the wash. Decant the wash and repeat four (4) additional times.**
8. Add 0.100 ml (100 μ l) of working signal reagent to all wells (see Reagent Preparation Section). **Always add reagents in the same order to minimize reaction time differences between wells.**
DO NOT SHAKE THE PLATE AFTER SIGNAL ADDITION
9. Incubate for five (5) minutes in the dark.
10. Read the relative light units in each well for 0.2 – 1.0 seconds. **The results should be read within thirty (30) minutes of adding the signal solution.**

10.0 CALCULATION OF RESULTS

A dose response curve is used to ascertain the concentration of CEA in unknown specimens.


1. Record the RLUs (*Relative Light Units*) obtained from the printout of the microplate reader as outlined in Example 1.
2. Plot the RLUs for each duplicate serum reference versus the corresponding CEA concentration in ng/ml on linear graph paper (do not average the duplicates of the serum references before plotting).
3. Draw the best-fit curve through the plotted points.
4. To determine the concentration of CEA for an unknown, locate the average RLUs for each unknown on the vertical axis of the graph, find the intersecting point on the curve, and read the concentration (in ng/ml) from the horizontal axis of the graph (the duplicates of the unknown may be averaged as indicated). In the following example, the average RLUs (10396) of the unknown intersects the calibration curve at (24.3ng/ml) CEA concentration (See Figure 1)*.

Note: Computer data reduction software designed for CLIA assay may also be used for the data reduction. **If such software is utilized, the validation of the software should be ascertained.**

EXAMPLE 1

Sample I.D.	Well Number	RLU (A)	Mean RLU (B)	Value (ng/ml)
Cal A	A1	26	25	0
	B1	23		
Cal B	C1	1469	1463	5
	D1	1457		
Cal C	E1	3901	3869	10
	F1	3838		
Cal D	G1	10832	10704	25
	H1	10576		
Cal E	A2	22207	21226	50
	B2	20246		
Cal F	C2	99288	100000	250
	D2	100712		
Patient	A3	10188	10396	24.3
	B3	10604		

Figure 1



* The data presented in Example 1 and Figure 1 is for illustration only and **should not** be used in lieu of a dose response curve prepared with each assay. In addition, the RLU's of the calibrators have been normalized to 100,000 RLU's for the F calibrator (greatest light output). This conversion eliminates differences caused by efficiency of the various instruments that can be used to measure light output.

11.0 Q.C. PARAMETERS

In order for the assay results to be considered valid the following criteria should be met:

1. The Dose Response Curve (80%; 50% & 20% intercepts) should be within established parameters.
2. Four out of six quality control pools should be within the established ranges.

12.0 RISK ANALYSIS

The MSDS and Risk Analysis Form for this product are available on request from Monobind Inc.

12.1 Assay Performance

1. It is important that the time of reaction in each well is held constant to achieve reproducible results.
2. Pipetting of samples should not extend beyond ten (10) minutes to avoid assay drift.
3. Highly lipemic, hemolyzed or grossly contaminated specimen(s) should not be used.
4. If more than one (1) plate is used, it is recommended to repeat the dose response curve.
5. The addition of signal reagent initiates a kinetic reaction, therefore the signal reagent(s) should be added in the same sequence to eliminate any time-deviation during reaction.
6. Failure to remove adhering solution adequately in the aspiration or decantation wash step(s) may result in poor replication and spurious results.
7. Use components from the same lot. No intermixing of reagents from different batches.
8. Patient specimens with CEA concentrations above 250 ng/ml may be diluted (for example 1/10 or higher) with normal male serum (CEA < 5 ng/ml) and re-assayed. The sample's concentration is obtained by multiplying the result by the dilution factor (10).
9. Accurate and precise pipetting, as well as following the exact time and temperature requirements prescribed are essential. Any deviation from Monobind IFU may yield inaccurate results.
10. All applicable national standards, regulations and laws, including, but not limited to, good laboratory procedures, must

be strictly followed to ensure compliance and proper device usage.

11. It is important to calibrate all the equipment e.g. pipettes, readers, washers and/or the automated instruments used with this device, and to perform routine preventative maintenance.
12. Risk Analysis- as required by CE Mark IVD Directive 98/79/EC - for this and other devices, made by Monobind, can be requested via email from Monobind@monobind.com.

12.2 Interpretation

1. Measurements and interpretation of results must be performed by a skilled individual or trained professional.

2. Laboratory results alone are only one aspect for determining patient care and should not be the sole basis for therapy, particularly if the results conflict with other determinants.
3. The reagents for AccuLite® CLIA procedure have been formulated to eliminate maximal interference; however, potential interactions between rare serum specimens and test reagents can cause erroneous results. Heterophilic antibodies often cause these interactions and have been known to be problems for all kinds of immunoassays (Boscato, LM, Stuart, MC. "Heterophilic antibodies: a problem for all immunoassays" *Clin. Chem.* 1988: 3427-33). For diagnostic purposes, the results from this assay should be used in combination with clinical examination, patient history and all other clinical findings.

4. For valid test results, adequate controls and other parameters must be within the listed ranges and assay requirements.
5. If test kits are altered, such as by mixing parts of different kits, which could produce false test results, or if results are incorrectly interpreted, **Monobind shall have no liability.**
6. If computer controlled data reduction is used to interpret the results of the test, it is imperative that the predicted values for the calibrators fall within 10% of the assigned concentrations.
7. CEA has a low clinical sensitivity and specificity as a tumor marker. **Clinically an elevated CEA value alone is not of diagnostic value as a test for cancer and should only be used in conjunction with other clinical manifestations (observations) and diagnostic parameters.** There are patients with colorectal cancer that do not exhibit elevated CEA values and elevated CEA values do not always change with progression or regression of disease. Smokers demonstrate a higher range of baseline values than non-smokers.

13.0 EXPECTED RANGES OF VALUES

Nearly 99% of non-smokers have CEA concentrations less than 5.0 ng/ml. Similarly 99% of smokers have concentrations less than 10ng/ml.*

TABLE 1

Expected Values for the CEA Test System	
Non-smokers	<5ng/ml
Smokers	<10ng/ml

It is important to keep in mind that establishment of a range of values which can be expected to be found by a given method for a population of "normal"-persons is dependent upon a multiplicity of factors: the specificity of the method, the population tested and the precision of the method in the hands of the analyst. For these reasons each laboratory should depend upon the range of expected values established by the Manufacturer only until an in-house range can be determined by the analysts using the method with a population indigenous to the area in which the laboratory is located.

14.0 PERFORMANCE CHARACTERISTICS

14.1 Precision

The within and between assay precision of the CEA AccuLite® CLIA Test System were determined by analyses on three different levels of control sera. The number, mean value, standard deviation (σ) and coefficient of variation for each of these control sera are presented in Table 2 and Table 3.

TABLE 2

Within Assay Precision (Values in ng/ml)				
Sample	N	X	σ	C.V.
Level 1	14	1.08	0.12	10.8%
Level 2	14	10.68	0.62	5.8%
Level 3	14	17.25	0.70	4.1%

TABLE 3

Between Assay Precision* (Values in ng/ml)				
Sample	N	X	σ	C.V.
Level 1	20	1.30	0.16	12.2%
Level 2	20	10.86	1.73	11.9%
Level 3	20	18.58	1.73	9.3

*As measured in ten experiments in duplicate.

14.2 Sensitivity

The CEA AccuLite® CLIA Test System has a sensitivity of 0.0028ng/well. This is equivalent to a sample containing 0.112ng/ml CEA concentration. The sensitivity was ascertained by determining the variability of the 0 ng/ml serum calibrator and using the 2σ (95% certainty) statistic to calculate the minimum dose.

14.3 Accuracy

The CEA AccuLite® CLIA Test System was compared with a reference method. Biological specimens from low, normal, and elevated concentrations were assayed. The total number of such specimens was 202. The least square regression equation and the correlation coefficient were computed for the CEA AccuLite® CLIA in comparison with the reference method. The data obtained is displayed in Table 4.

TABLE 4

Method	Mean (x)	Least Square Regression Analysis	Correlation Coefficient
Monobind (y)	5.67	y = 1.0324(x) + -0.1164	0.985
Reference (x)	5.75		

14.4 Specificity:

Highly specific antibodies to CEA molecules have been used in the CEA AccuLite® CLIA Test System. No interference was detected with the performance of CEA AccuLite® CLIA upon addition of massive amounts of the following substances to a human serum pool.

Substance	Concentration
Acetylsalicylic Acid	100 µg/ml
Ascorbic Acid	100 µg/ml
Caffeine	100 µg/ml
AFP	10 µg/ml
PSA	1 µg/ml
CA-125	10,000 U/ml
hCG	1000 IU/ml
hLH	10 IU/ml
hTSH	100 mIU/ml
hPRL	100 µg/ml

14.5 Linearity & Hook Effect:

Three different lot preparations of the CEA AccuLite® CLIA reagents were used to assess the linearity and hook effect. Massive concentrations of CEA (> 60,000 ng/ml) were used for linear dilutions in pooled human patient sera.

The test showed no hook effect up to concentrations of 60,000 ng/ml and a within dose recovery of 96.0 to 108.2%.

15.0 REFERENCES

1. Gold P, Freedman SO, *J Exp Med*, 121, 439 (1965).
2. Zamcheck N, *Adv Intern Med*, 19, 413 (1974).
3. Rayncao G, Chu TM, *JAMA*, 220, 381 (1972).
4. Wild D, *The Immunoassay Handbook*, Stockton Press, 444 (1994).
5. Sorokin JJ, Sugarbaker PH, Zamcheck N, Pisick M, Kupchik HZ, Moore FD, "Serial carcinoembryonic antigen assays. Use in detection of cancer recurrence", *JAMA*, 228, 49-53 (1974).
6. Mackay AM, Patel S, Carter S, Stecens U, Lawrence DJR, Cooper EH, et al. "Role of serial plasma assays in detection of recurrent and metastatic colorectal carcinomas". *Br. Med. J.* 1974; 4:382-385.
7. Sikorska H, Schuster J, Gold P, "Clinical applications of carcinoembryonic antigen", *Cancer Detection Preview*, 12, 321-355 (1988).
8. Minton JP, Martin, EW Jr., "The use of serial CEA determinations to predict recurrence of colon cancer and when to do a second-look surgery", *Cancer*, 42, 1422-27 (1978).
9. Staab HJ, Anderer FA, Stumpf E, Fischer R. "Slope analysis of the postoperative CEA time course and its possible application

as an aid in diagnosis of disease progression in gastrointestinal carcinoma". *Am. J.Surgery*, 136: 322-327 (1978).

10. Thomas P, Toth CA, Saini KS, Jesup JM, Steele G Jr, "The structure, metabolism and function of carcinoembryonic antigen gene family", *Biochem Biophys Acta*, 1032,177-189 (1990).
11. Yamashita K, Totami K, Kuroki M, Ueda I, Kobata A, "Structural studies of the carbohydrate moieties of carcinoembryonic antigens", *Cancer Research*, 47, 3451-3459 (1987).
12. Hammerstrom S, Shively JE, Paxton RJ, Beatty BG, Larson A, Ghosh R, et al. "Antigenic sites in carcinoembryonic antigen", *Cancer Research*, 49,4852-58 (1989).
13. National Institute of Health, "Carcinoembryonic Antigen: Its role as a marker in the management of cancer; A National Institute of Health Consensus Development Conference", *Ann Intern Med*, 94,407-409 (1981).

Effective Date: 2019-Jul-16 Rev 6
MP1875

DCO: 1353
Product Code: 1875-300

Reagent (fill)	Size	96 (A)	192 (B)
	A)	1ml set	1ml set
B)	1 (13ml)	2 (13ml)	
C)	1 plate	2 plates	
D)	1 (20ml)	1 (20ml)	
E)	1 (7ml)	2 (7ml)	
F)	1 (7ml)	2 (7ml)	

For Orders and Inquires, please contact

Monobind Inc.
100 North Pointe Drive
Lake Forest, CA 92630 USA

Tel: +1 949.951.2665 Mail: info@monobind.com
Fax: +1 949.951.3539 Fax: www.monobind.com



Please visit our website to learn more about our products and services.

Glossary of Symbols
(EN 980/ISO 15223)

